A) Synageva B) Proliferon C) Enobia Pharma D) Caelum Biosciences
A) $8.4 billion B) $855 million C) $41 million D) $1.08 billion
A) Alexion Antibody Technologies B) Alexion Rare Disease C) Alexion Biopharma D) Alexion Hematology
A) April 2018 B) September 2000 C) June 2015 D) December 2011
A) Synageva treatment B) Factor Xa inhibitor C) asfotase alfa D) Proliferon serum
A) hematology disorders B) immune system disease C) hypophosphatasia D) neurology disorders
A) $8.4 billion B) $41 million C) $1.08 billion D) $500 million
A) Syntimmune B) Achillion Pharmaceuticals C) Synageva D) Wilson Therapeutics
A) $930 million B) $855 million C) $1.2 billion D) $8.4 billion
A) Wilson Therapeutics B) Portola Pharmaceuticals C) Proliferon D) Caelum Biosciences
A) $855 million B) $500 million C) $930 million D) $1.2 billion
A) Syntimmune B) Achillion Pharmaceuticals C) Enobia Pharma D) Synageva
A) $8.4 billion B) $1.2 billion C) $1.08 billion D) $41 million
A) Achillion Pharmaceuticals B) Caelum Biosciences C) Portola Pharmaceuticals D) Wilson Therapeutics
A) $500 million B) $930 million C) $855 million D) $1.2 billion
A) Expanding into hematology B) Adding Factor Xa inhibitor C) Acquiring asfotase alfa D) Boosting immune system disease pipeline
A) Portola Pharmaceuticals B) Enobia Pharma C) Syntimmune D) Synageva
A) Hematology, neurology, and critical care portfolio B) Immune system disease pipeline C) Development-stage biopharma holdings D) Rare disease offerings only
A) Factor Xa inhibitor reversal agent B) asfotase alfa C) hypophosphatasia treatment D) Caelum therapeutics
A) October 2021 B) November 2018 C) January 2020 D) July 2020
A) $930 million B) $500 million C) $41 million D) $855 million
A) Yale New Haven Hospital B) Honeywell C) Moderna D) AstraZeneca
A) Boston, Massachusetts B) Smithfield, Rhode Island C) New Haven, Connecticut D) Cheshire, Connecticut
A) Orphan drugs for rare diseases B) Oncology chemotherapy C) Vaccine distribution D) Common cold medications
A) Strensiq B) Soliris C) Ultomiris D) Andexxa
A) Treat liver failure B) Stop life-threatening bleeding C) Cure bone fractures D) Reduce cholesterol
A) 2010 B) 2015 C) 1992 D) 2000
A) 2021 B) 2010 C) 2007 D) 2015
A) Honeywell B) Moderna C) AstraZeneca D) PhRMA
A) Soliris B) Ultomiris C) Strensiq D) Kanuma
A) Ludwig N. Hantson B) David Hallal C) David Anderson D) David Brennan
A) Lysosomal acid lipase deficiency B) Hypophosphatasia C) Influenza D) Escherichia coli (EHEC)
A) Boston, Massachusetts B) Cheshire, Connecticut C) Smithfield, Rhode Island D) New Haven, Connecticut
A) 2010 B) 2016 C) 2021 D) 1992
A) David Anderson B) Steven Squinto C) Ludwig N. Hantson D) David Hallal |